VIVUS and Alvogen Announce Marketing Agreement for Qsymia

VIVUS (NASDAQ:VVUS) announced a new agreement in which Alvogen Malta Operations will market Qsymia in the Republic of Korea for the treatment of chronic weight management or weight-related conditions.
As quoted in the press release:

Under the terms of the agreement, Alvogen, a prominent leader in the Korean anti-obesity market, will be solely responsible for obtaining and maintaining regulatory approvals and for all sales and marketing activities in Korea. VIVUS will receive an upfront payment in addition to future milestone payments, dependent upon receiving marketing authorization, initiating the commercial launch and achieving sales goals within the covered territory. In addition, VIVUS will receive royalties on Alvogen’s net sales of Qsymia.
“With manufacturing centers in Korea and hundreds of products on the market in Asia, Alvogen has the expertise and relationships that we believe will be essential for making Qsymia a success in Korea,” said Seth H. Z. Fischer, VIVUS’ Chief Executive Officer.

Click here to read the full press release.

Source: www.marketwired.com